With recent approval of the first two gene therapies for haemophilia A and B,...
Read More
Hemophilia B (HB) is a rare, hereditary disease caused by a defect in the...
Thromboembolic events are increasingly reported in the aging haemophilia population. The purpose of this...
Haemophilia treatment centres (HTCs) and healthcare providers (HCPs) will need to adapt to a...
After decades of investigation, gene therapy has received regulatory approval to treat hemophilia. However,...
Primary prophylaxis has significantly reduced the number of orthopedic surgical procedures performed on patients...
The standard of care in severe haemophilia A is prophylaxis, which has historically aimed...
Hemophilia A is characterized by a deficiency of clotting factor VIII (FVIII) requiring lifelong...
Gene therapy is expected to become a promising treatment, and potentially even cure, for hemophilia....
Over the last decade, the world of hemophilia has experienced an unprecedented therapeutic advance,...